Timothy P M Whelan
Overview
Explore the profile of Timothy P M Whelan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
326
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Klipsch E, Rodgers J, Sokevitz K, Kwon J, Shorbaji K, Bostock I, et al.
JTCVS Open
. 2025 Jan;
22():504-518.
PMID: 39780783
Objective: Racial disparities in organ allocation may result in differential survival for marginalized groups. This study aims to examine the impact of the November 2017 lung allocation policy change (LAPC)...
2.
Pugashetti J, Kim J, Combs M, Ma S, Adegunsoye A, Linderholm A, et al.
J Heart Lung Transplant
. 2024 Mar;
43(7):1174-1182.
PMID: 38556070
Background: Lung transplantation remains the sole curative option for patients with idiopathic pulmonary fibrosis (IPF), but donor organs remain scarce, and many eligible patients die before transplant. Tools to optimize...
3.
Lindell K, Madisetti M, Fasolino T, Pittman M, Coyne P, Whelan T, et al.
Palliat Med Rep
. 2023 Nov;
4(1):292-299.
PMID: 37915951
Background: Idiopathic pulmonary fibrosis (IPF) is a serious illness with an unpredictable disease course and survival rates comparable with some cancers. Patients with IPF suffer considerable symptom burden, declining quality...
4.
Swaminathan A, Hellkamp A, Neely M, Bender S, Paoletti L, White E, et al.
Ann Am Thorac Soc
. 2022 Jan;
19(6):981-990.
PMID: 35073248
Lung transplant offers the potential to extend life for patients with idiopathic pulmonary fibrosis (IPF); yet, this therapeutic modality is only available to a small proportion of patients. To identify...
5.
Raghu G, Brown K, Collard H, Cottin V, Gibson K, Kaner R, et al.
Lancet Respir Med
. 2016 Dec;
5(1):22-32.
PMID: 27939076
Background: Lysyl oxidase-like 2 (LOXL2) catalyses collagen cross-linking and is implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF). The aim of this study was to investigate the efficacy and...
6.
Bors M, Tomic R, Perlman D, Kim H, Whelan T
Chron Respir Dis
. 2015 Sep;
12(4):365-72.
PMID: 26374298
The purpose of this study was to investigate whether there is evidence that individuals with severe idiopathic pulmonary fibrosis (IPF) have cognitive deficits when compared to individuals with healthy lungs....
7.
Kotloff R, Blosser S, Fulda G, Malinoski D, Ahya V, Angel L, et al.
Crit Care Med
. 2015 May;
43(6):1291-325.
PMID: 25978154
This document was developed through the collaborative efforts of the Society of Critical Care Medicine, the American College of Chest Physicians, and the Association of Organ Procurement Organizations. Under the...
8.
Kummerfeldt C, Huggins J, Riemer E, Ravenel J, Whelan T, Sahn S
Int J Rheum Dis
. 2013 Jun;
16(2):233-4.
PMID: 23773650
No abstract available.
9.
Whelan T
Clin Chest Med
. 2012 Feb;
33(1):179-89.
PMID: 22365254
For selected parenchymal lung disease patients who fail to respond to medical therapy and demonstrate declines in function that place them at increased risk for mortality, lung transplantation should be...
10.
Whitson B, Prekker M, Herrington C, Whelan T, Radosevich D, Hertz M, et al.
J Heart Lung Transplant
. 2007 Oct;
26(10):1004-11.
PMID: 17919620
Background: Severe primary graft dysfunction (PGD) is associated with poor early outcomes after lung transplantation (LTx). Less is known about lingering effects of severe PGD on pulmonary function. The study's...